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Abstract
Background: The Runt-related transcription factor Runx2 is essential for bone development but is also implicated in
progression of several cancers of breast, prostate and bone, where it activates cancer-related genes and promotes
invasive properties. The transforming growth factor β (TGF-β) family member bone morphogenetic protein-3B
(BMP-3B/GDF10) is regarded as a tumor growth inhibitor and a gene silenced in lung cancers; however the
regulatory mechanisms leading to its silencing have not been identified.
Results: Here we show that Runx2 is highly expressed in lung cancer cells and downregulates BMP-3B. This inverse
relationship between Runx2 and BMP-3B expression is further supported by increased expression of BMP-3B in
mesenchymal cells from Runx2 deficient mice. The ectopic expression of Runx2, but not DNA binding mutant
Runx2, in normal lung fibroblast cells and lung cancer cells resulted in suppression of BMP-3B levels. The chromatin
immunoprecipitation studies identified that the mechanism of Runx2-mediated suppression of BMP-3B is due to the
recruitment of Runx2 and histone H3K9-specific methyltransferase Suv39h1 to BMP-3B proximal promoter and a
concomitant increase in histone methylation (H3K9) status. The knockdown of Runx2 in H1299 cells resulted in
decreased histone H3K9 methylation on BMP-3B promoter and increased BMP-3B expression levels. Furthermore,
co-immunoprecipitation studies showed a direct interaction of Runx2 and Suv39h1 proteins. Phenotypically, Runx2
overexpression in H1299 cells increased wound healing response to TGFβ treatment.
Conclusions: Our studies identified BMP-3B as a new Runx2 target gene and revealed a novel function of Runx2 in
silencing of BMP-3B in lung cancers. Our results suggest that Runx2 is a potential therapeutic target to block tumor
suppressor gene silencing in lung cancer cells.
Keywords: Lung cancer, Runx2, BMP-3B, Gene silencing
Background
Lung cancer is the leading cause of cancer mortality and
accounts for 30% of all deaths from cancer [1]. Silencing
of tumor suppressor genes by aberrant promoter hyper-
methylation is a key event in lung cancer initiation and
progression. During gene silencing, the chromatin struc-
ture is altered by acetylation, phosphorylation and
methylation of histone tails [2]. These alterations in
chromatin structure affect normal cell functions and are
a crucial trigger for neoplastic development and progres-
sion [3]. However, current understanding of regulatory
mechanisms of silencing of tumor suppressors is limited.
In this study we identified a mechanism by which Runx2
transcription factor contribute to epigenetic silencing of
a tumor growth inhibitor BMP-3B in lung cancer cells.
Runx transcription factors (Runx1, Runx2 and
Runx3) are critical regulators of organogenesis and
cell differentiation regulatory pathways, and mutations
in these genes are associated with several cancers.
Runx2, an essential bone cell differentiation factor
[4,5] is recently implicated in mammary, prostate and
osteosarcoma progression [6-8]. In cancer cells, Runx2
activates cancer-related genes, promotes cells invasive
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in T-cell lymphoma development), and suppresses apop-
totic and growth arrest pathways [11,12]. Runx2 is also a
major target gene of TGFβ /BMP signaling pathway and
the interaction between Runx2 and Smads results in regu-
lation of downstream target genes in osteoblasts [13],
chondrocytes [14] and cancer cells [8].
BMP-3B, a TGFβ family member and closely related
to BMP-3, is highly expressed in lung [15-17], brain
and bone tissues, and induces bone formation [18,19].
Ectopic BMP-3B expression promotes osteoblast differ-
entiation and augments the bone formation induced by
bone morphogenetic protein-2 (BMP-2) in rats [20].
Importantly, the expression of BMP-3B is downregu-
lated in lung cancer patient samples and cancer cells
lines compared to normal lung cells [21-23]. Multiple
mechanisms have been proposed for the downregulation
of BMP-3B levels which include methylation of gene
promoter and repression by transcription factors [21]
however, the transcriptional repressor proteins of BMP-3B
are unknown.
We show that BMP-3B is a novel Runx2 target gene
and find an inverse relationship between Runx2 and
BMP-3B expression levels in normal lung fibroblast and
lung cancer cells. Our studies with Runx2 overexpres-
sion or knockdown in lung cancer cells indicate that
Runx2-mediated downregulation of BMP-3B is via
increasing histone H3K9 methylation status of the
proximal promoter by interacting with methyltransre-
fase Suv39h1.
Results
Calvarial mesenchymal cells of Runx2-deficient mice have
higher expression levels of BMP-3B
To identify novel Runx2 target genes, we performed cDNA
expression analysis on total RNA isolated from calvarial
mesenchymal cells of wild type and functional deficient
Runx2 mice [5]. In addition to the downregulation of
known Runx2 target genes (e.g., matrix metalloproteinases)
in a osteogenesis-related cDNA array [24], we found that
the expression levels of BMP-3B gene was induced in
Runx2 deficient cells compared to wild type cells
(Figure 1a). The induction of BMP-3B expression in
Runx2 deficient calvarial mesenchymal cells was vali-
dated by qRT-PCR analysis (Figure 1b). To further
confirm Runx2-mediated downregulation of BMP-3B
levels, we re-expressed Runx2 via adenoviral delivery
in Runx2 deficient primary calvarial cells and measured
BMP-3B levels by qRT-PCR analysis (Figure 1c). Our
results show a dose-dependent repression of BMP-3B
mRNA levels by Runx2 in primary osteoblastic cells.
These results suggested that BMP-3B is a novel Runx2
responsive gene.
An inverse relationship between Runx2 and BMP-3B
expression levels in lung cancer cells
A tumor growth inhibitory function was proposed for
BMP-3B in lung cancers and BMP-3B is downregulated
in most of the lung cancers [22,23,25]. In context of
Runx2-mediated BMP-3B suppression in mesenchymal
cells and to understand the upstream regulatory
mechanisms of BMP-3B silencing in lung cancers, we
hypothesized that Runx2 downregulates BMP-3B expres-
sion in lung cancer. To understand the role of Runx2 in
BMP-3B transcriptional regulation in lung cancer cells,
we first examined Runx2 and BMP-3B mRNA levels in
normal lung fibroblasts of mesenchymal origin (WI-38
and IMR-90), atypical carcinoid (H720) and meta-
static non-small cell lung carcinoma (H1299) cells by
qRT-PCR analysis. Our results showed that Runx2
expression is increased in metastatic lung cancer cells
(H1299) compared to normal lung fibroblast cells. In
contrast to the Runx2 expression levels, BMP-3B
mRNA was detectable but lower in lung cancer cells
compared to normal lung fibroblast cells (Figure 1d
and e). The Western blot analysis for Runx2 protein
levels further validated increased Runx2 levels in lung
cancer cells compared to normal lung fibroblast cells
(Figure 1f). A punctate nuclear staining of Runx2
was observed in WI-38 and H1299 cells as examined
by immunofluorescence (Figure 1g). Taken together,
these studies revealed that the inverse relationship
between Runx2 and BMP-3B levels observed in cal-
varial mesenchymal cells also holds true for normal
lung fibroblasts and lung cancer cells.
Runx2 overexpression suppresses BMP-3B in lung cancer
cells
To investigate whether Runx2 suppresses BMP-3B levels
in lung cancer cells similar to observed in primary cal-
varial cells, we stably overexpressed wild type Runx2
(WT) and Runx2 DNA binding domain mutant (DBD)
in normal lung fibroblast cells (WI-38 and IMR-90) by
lentiviral-mediated gene delivery. Expression levels of
wild type and mutant Runx2 protein in these cell types
were confirmed by qRT-PCR and western blot analysis
(data not shown). Our results showed that stable expres-
sion of wild type Runx2 in normal lung cells resulted in
more than 2-fold decrease in BMP-3B levels compared
to empty vector control cells (Figure 2a and b). Ectopic
expression of DBD mutant of Runx2 failed to downregu-
late BMP-3B levels in normal lung or lung cancer cells.
These results suggested that the Runx2 DNA binding
activity is required for BMP-3B regulation. In complemen-
tary studies, Runx2 knockdown resulted in increased BMP-
3B levels in normal bronchial NL-20 cells (10- fold increase,
Figure 2c right panel) and H1299 cells (2-fold increase,
Figure 2d right panel) compared to empty vector controls
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levels in Runx2 knockdown cells was confirmed by qRT-
PCR and western blot analysis (Figure 2c and d). Collect-
ively, these results indicate that Runx2 downregulates BMP-
3B levels in normal lung fibroblast and lung cancer cells.
Runx2 recruitment on the BMP-3B gene promoter and
interaction with Suv39h1 promotes BMP-3B silencing
To further investigate the mechanism of Runx2-mediated
downregulation of the BMP-3B expression in lung cancer
cells, we performed chromatin immunoprecipitation ana-
lysis in H1299 cells expressing either wild type Runx2 or
shRunx2 (Figure 3). Our results showed 3-fold increased
Runx2 binding on the BMP-3B proximal promoter
(-1.0kb) in H1299-WT-Runx2 cells, that was abrogated in
H1299-shRunx2 cells. We next examined the methylation
status of the BMP-3B proximal promoter as methylation
of lysine 9 of histone H3 (H3K9) allows the binding of het-
erochromatin protein- 1 (HP1) to silence gene expression
[26,27]. Our results show increased (3-fold) H3K9 levels of
proximal promoter region of BMP-3B in H1299-Runx2
cells compared to H1299-shRunx2 cells or antibody con-
trols (Figure 3a). We next examined the recruitment of
Suv39h1 protein, a histone H3 lysine 9 specific methyltrans-
ferase, on BMP-3B proximal promoter. A twofold increase
in recruitment of Suv39h1 was observed in H1299-Runx2
cells compared to H1299-shRunx2 lung cancer cells
(Figure 3a). These findings indicated the possibility of
physical interaction of Runx2 and Suv39h1 proteins in
lung cancer cells. We performed co-immunoprecipitaion
assays with Runx2 and Suv39h1 antibodies and a direct
interaction of Runx2 with Suv39h1 proteins was detected in
H1229 cells (Figure 3b). Taken together, these results show
that the recruitment of Runx2 and Suv39h1 on the BMP-3B
Figure 1 Runx2 deficient mice have higher levels of BMP-3B. (a) Total RNA from mesenchymal cells of calvarial tissue from wild type and
Runx2
-/- (17.5 dpc) was hybridized with osteogenesis-related cDNA array. Signal of BMP-3B on blots is indicated by an arrow. Control genes
(GAPDH, cyclophilin A) are shown in lower panel. (b) BMP-3B mRNA levels (normalized to GAPDH) in calvarial mesenchymal cells from wild type
(WT) and Runx2
-/- animals as detected by qRT-PCR analysis. (c) Primary calvarial cells from Runx2 deficient animals were transduced with empty
vector (EV) or Runx2 expressing adenovirus with increasing multiplicity of infection (MOI 10 and 20) for 48 hr. Total RNA isolated from the infected
cells was utilized to examine BMP-3B mRNA as detected by qRT-PCR analysis. (d) Runx2 mRNA expression levels were examined by qRT-PCR and
the gene expression levels were normalized to 28S internal control. The gene expression levels were calibrated to IMR-90 cells. (e) BMP-3B mRNA
expression levels were examined by qRT-PCR and the gene expression levels were normalized to 28S internal control. The BMP-3B gene
expression levels were calibrated to Runx2 levels in IMR-90 cells. (f) Runx2 protein levels were examined in nuclear extracts of normal lung
fibroblast cells (IMR-90 and WI-38) and lung cancer cell lines (H720 and H1299) by immunoblotting with Runx2 monoclonal antibody. Runx2
expression levels were normalized to internal control LaminA/C protein. (g) Runx2 intracellular localization was determined by
immunofluorescence of endogenous Runx2 protein in WI-38 and H1299 cells. The punctate (Alexa 488, green) signal shows Runx2 staining while
nuclei are revealed by 4, 6-diamidino-2-phenylindole (DAPI, blue) staining.
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methylation status and consequently downregulation of
BMP-3B expression in lung cancer cells.
Runx2 increases wound-healing response of lung cancer
cells
To examine the phenotypic effects of Runx2 overexpression
in lung cancer cells, we assessed proliferation and migration
potential of H1299-Runx2 cells or H1299- empty vector
cells. Increased Runx2 levels in H1299-Runx2 cells and a
corresponding decrease in BMP-3B mRNA expression were
confirmed by western blot and qRT-PCR analysis respect-
ively (Figure 4a). A 40% decline in cell proliferation was
observed in Runx2 overexpressing H1299 cells compared to
empty vector control cells in absence or presence of TGFβ
treatment as examined by cell growth assay (data not
shown) and MTT assays (Figure 4b). However, in response
to TGF-β treatment the Runx2 overexpression in H1299
cells resulted in a significant (p <0.05) increase in wound
healing response compared to the empty vector control for
6-48h as shown by wound healing assay (Figure 4c). The
H1299 EV or WT-Runx2 cells did not show any differences
in KI-67 (cell proliferation marker) immunoreactivity
around wound area (data not shown). These results suggest
that Runx2 promotes migratory potential of lung cancer
cells by modulating TGF-β/BMP-3B signaling axis.
Discussion
Our studies identify BMP-3B as a Runx2 target gene and
show that Runx2 promotes epigenetic silencing of BMP-3B
Figure 2 Runx2 suppresses BMP-3B in lung cancer cells. (a and b) Expression levels of BMP-3B in normal lung fibroblast cells (a: WI-38, b:
IMR-90) transduced with wild type Runx2 (WT), functional deficient mutant (DBD: DNA binding domain mutant,) and empty vector (EV) control
lentiviral particles are shown as detected by qRT-PCR analysis. (c and d) The Runx2 protein was suppressed in normal bronchial NL-20 epithelial
cells and H1299 lung cancer cells by lentiviral vector-mediated RNAi. The suppression of Runx2 at mRNA and protein expression levels is shown
for NL-20 cells (C top left and lower left panels). The mRNA levels of BMP-3B in Runx2 suppressed NL-20 and control cells are shown as examined
by qRT-PCR (C top right panel). The suppression of Runx2 at mRNA and protein expression levels is shown for H1299 cells (D top left and lower
left panels). The mRNA levels of BMP-3B in Runx2 suppressed H1299 and control cells as examined by qRT-PCR (D top right panel).
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tion status of the proximal regulatory regions. The Runx2
interaction with Suv39h1 methyltransferase and binding to
the BMP-3B promoter results in downregulation of the
BMP-3B expression levels. Furthermore, ectopic expression
of Runx2 enhances the migration potential of lung cancer
cells in response to the TGFβ signaling.
We find that mesenchymal cells from Runx2-deficient
animals express high levels of BMP-3B compared to wild
type cells. In contrast to high levels of BMP-3B, low
baseline levels of BMP2 are reported in Runx2 deficient
cells that can be up-regulated by ectopic expression of
Runx2 [28]. Interestingly, a BMP2 orthologous signaling
antagonizing function for BMP3/3B has been proposed
during embryonic development of xenopus [29]. In
addition to directly regulating expression levels of BMP
family members as shown by these studies, Runx2-Smad
complex has been shown to regulate expression of genes
related to osteogenic [10,30,31] and cancer [32] properties
in response to TGFβ/BMP signaling. The consequences of
direct regulation of BMP-3B by Runx2 on downstream mo-
lecular events of TGFβ/BMP pathway still need to be deter-
mined. A recent report shows that the migration of lung
cancer cells is associated with the upregulation of Runx2
and Snail expression in response to BMP-2 treatment [33].
Our results show that Runx2 downregulates BMP-3B and
increases migration potential of lung cancer cells in re-
sponse to TGFβ treatment. These studies suggest that
cross-talk between Runx2 and TGFβ/BMP signaling is dif-
ferential and could be context-dependent.
Figure 3 Runx2 recruitment on BMP-3B gene promoter and interaction with Suv39h1. (a) Lung cancer cells (H-1299) stably expressing wild
type Runx2 (left panel) or shRNA-Runx2 (right panel) were subjected to chromatin immunoprecipitation assay with Runx2, Suv39h1, H3K9 or
control IgG-G (goat) and IgG-R (rabbit) antibodies. Immunoprecipitated DNA samples were further amplified by real-time qPCR with primer pairs
for proximal promoter (-1.0kb) of BMP-3B gene. A schematic diagram above indicates Runx binding motifs (solid bars) on BMP-3B promoter. The
BMP-3B ChIP primer pairs are indicated by arrows in the schematic diagram. (b) Co-immunoprecipitation assay shows Runx2 interaction with
Suv39h1 in H-1299 lung cancer cells. Whole cell extracts from lung cancer H-1299 cells were incubated with Runx2, Suv39h1 or control IgG
antibodies. Western blots showing Runx2 and Suv39h1 proteins as detected by αRunx2 and αSuv39h1 antibodies.
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levels of Runx2 in lung cancer cells compared to normal
lung fibroblast cells are consistent with previous reports of
Runx2 expression in other epithelial cancers like breast and
prostate cancers [8,10,31,34-36]. The Runx2 gene expres-
sion levels were similar in IMR-90 and WI-38 cells; how-
ever BMP-3B levels were dramatically reduced suggesting
cell-type-specific differences. In addition, we find that the
Runx2 overexpression in lung cancer cells results in a sig-
nificant decline in cell proliferation but enhances wound
healing response. In serum-deprived conditions used for
the wound healing assay, we observed similar numbers of
KI-67 positive cells close to (200-400μm) wound area in
both EV and WT-Runx2 over-expressing cells. As we find
KI-67 positive cells in both groups, therefore, we cannot
completely rule out the possible contribution of cell prolif-
eration in the observed wound healing phenotype. This
phenotype is probably the combinatorial effect of Runx2
on BMP-3B suppression and activation of genes related to
invasion and migration (e.g., MMPs), as Runx2 is known to
promote migration and invasive potential of breast and
prostate cancer cells [6,8,9,24,33,35,37-39]. The down-
stream molecular events of BMP-3B silencing in lung can-
cer progression are still not clear and might include
phosphorylation of Smad proteins as recently reported that
BMP-3B inhibits tumor formation of mammary tumor cells
by promoting phosphorylation of Smad3[40].
An important finding of our study is the identification
of mechanism where Runx2 protein downregulates
BMP-3B levels by interacting and recruitment of Suv39h1
methyltransferase at the proximal regulatory sequence.
Similar to our findings, a direct interaction of Suv39h1with
the C-terminal domain of other Runx family members
(Runx1 and Runx3) results in silencing of CD4 gene by
promoter methylation during T-cell development [41,42].
Runx2 is well known to regulate chromatin structure and
modulate target gene expression [43]. For example,
Runx2 interaction with p300 alters chromatin structure
Figure 4 Runx2 increases migration potential of lung cancer cells. (a) Left panel: Runx2 protein was overexpressed in H-1299 cells via
lentiviral vector-mediated gene transfer and overexpression levels are shown by Western blot analysis. Right panel: The mRNA levels of BMP-3B in
Runx2 overexpressed H1299 cells as examined by qRT-PCR (b) The Runx2 overexpressing H1299 cells or empty vector (control) were seeded in a
96 well cell culture dish in presence or absence of TGFβ (5ng/ml) and examined for changes in cell proliferation via cell proliferation MTT assay by
measuring absorbance at 490 nm. (c) Cell migration in H-1299 cells expressing Runx2 or empty vector control was examined in a standard
wound/scratch healing assay in response to TGF-β treatment. Representative images at 40X magnification and average (±standard deviation)
wound healing response is shown at indicated time points. (* P≤0.05).
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of MMP-13 gene in bone cell lineage in response to
PTH [44] and enhances histone acetylation resulting in
increased Snail expression and decreased E-cadherin in
lung cancer cells [33]. Recent reports indicate that
Runx2 forms complexes containing the RNA Pol I
transcription factors UBF1 and SL1, co-occupies the
rRNA gene promoter with these factors in vivo, and
affects local chromatin histone modifications at rDNA
regulatory regions during rDNA suppression [45,46].
Consistent with these studies, our results revealed that
Runx2 regulates histone H3K9 methylation status of
BMP-3B promoter in lung cancer cells. There is a pos-
sibility that Runx2 repressor complex on BMP-3B pro-
moter includes members of HDAC family as previously
shown for repressing bone sialoprotein gene expression
in osteoblastic lineage cells [47-49].
In summary, our study demonstrates BMP-3B as a
novel target gene for Runx2 in bone lineage and lung
cancer cells and provides insight into mechanisms that
regulate epigenetic silencing of tumor growth inhibitors
in lung cancer cells (Figure 5). Further studies are
required to definitely establish the contribution of Runx2
in lung cancer progression.
Conclusions
Taken together, our results identified BMP-3B as a new
Runx2 target gene and revealed a novel function of
Runx2 in epigenetic silencing of BMP-3B in lung can-
cer cells. Our studies with modulation of Runx2 levels
in lung cancer cells indicate that Runx2-mediated
downregulation of BMP-3B levels is via interacting
with methyltransrefase Suv39h1 and increasing histone
H3K9 methylation status of the proximal promoter.
These results suggest that Runx2 is a potential thera-
peutic target to block tumor suppressors gene silencing
in lung cancer cells.
Materials and methods
Cell Culture and treatments
Normal bronchial and lung fibroblast (NL-20; WI-38,
and IMR-90) and lung cancer cells (small cell lung
cancer and non-small cell lung cancer cells: H720, and
H1299) were cultured in growth medium as specified
by American Type Culture Collection. The construction
and procedure for wild type Runx2 or DNA binding mu-
tant expressing adenovirus and lentivral transduction in
normal and cancer cells are reported previously [24,45].
Animal procedures
Animals were maintained at the University of Massachusetts
Medical School following procedures approved by the
Institutional Animal Care and Use Committee (IACUC).
Primary calvarial cells from Runx2
-/- mice were isolated
as previously described [24].
shRNA treatment
Normal bronchial NL-20 or lung cancer H-1299 cells
were transduced with lentivirus expressing shRNA-Runx2
target sequence 5’-AAGGTTCAACGATCTGAGATTTG-3’
Figure 5 Illustration of Runx2-mediated epigenetic silencing of BMP-3B in lung cancer cells. The recruitment of Runx2 and Suv39h1 on the
BMP-3B locus increases histone H3K9 methylation status resulting in downregulation of BMP-3B expression in lung cancer cells.
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Runx2 knockdown efficiency was confirmed by western blot
and real time RT-PCR analysis.
Western blot analysis
Runx2 protein levels in normal bronchial, fibroblast and
lung cancer whole cell lysates or nuclear lysates were
detected by western blot analysis as described previously
[24]. Runx2 antibody (MBL Inc., Woburn, MA) or
Suv39h1 (C-14, Santa Cruz Biotechnology Inc. Santa
Cruz, CA) and HRP-conjugated secondary antibodies
(Santa Cruz) were used to detect immunoreactive
proteins.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed
as previously described [34]. Protein-DNA complexes
were immunoprecipitated using Runx2 antibody (M-70,
Santa Cruz Biotechnology Inc.), Suv39h1 (Santa Cruz
Biotechnology Inc.) and histone H3K9 (Abcam, Cambridge,
MA) or IgG as a control. Purified DNA was subjected to
real time PCR amplification with SYBR Green chemistry on
an ABI real time thermocycler. BMP-3B promoter fragment
containing Runx elements were amplified using forward
primer: 5’ ACT TTG ATG AAT CCG CAA CC-3’ and re-
verse primer: 5’ TTG TCT TGC CTC TAGCAG GAT-3’.
Real time RT-PCR analysis
The mRNA levels of Runx2, BMP-3B, GAPDH and 28S
in primary osteoblasts, normal lung fibroblast, bronchial
and lung cancer cells were analyzed after adenovirus- or
lentiviral-mediated Runx2 transduction. Total RNA was
isolated using Trizol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s specification. Purified
RNA was oligo dT primed and cDNA synthesized at 42°
C with SuperScript II RNA polymerase (Invitrogen). For
PCR amplification, the following primers were used:
Runx2, forward primer: 5’- CGG CCC TCC CTG AAC
TCT -3’, reverse primer: 5’- TGC CTG CCT GGG GTC
TGT A -3’, GAPDH, forward primer: 5’-A T GT T CG T C
ATG GGT GTG AA -3’, reverse primer: 5’- TGT GGT
CAT GAG TCC TTC CA -3’. BMP-3B, forward primer:
5’-AGC TGC TGG ACT TTG ACG AG-3’, reverse pri-
mer: 5’-TGA CAA TGC TCT GGA TGG TG-3’. 28S,
forward primer: 5’- GAA CTT TGA AGG CCG AAG
TG-3’, reverse primer: 5’-ATC TGA ACC CGA CTC
CCT TT-3’. The gene expression levels were quantified
by ΔΔCt method of relative quantification by normaliz-
ing the data with internal control and expressed rela-
tive to appropriate control cell line as indicated in the
figure legends.
Wound healing assay
H1299 cells stably expressing Runx2 or empty vector
treated control cells were cultured in triplicates in a 6
well dish with reduced serum conditions (0.2% serum)
for overnight. The next day, a scratch was made approxi-
mately in the center of the monolayer by a sterile 200μl
pipette tip. The detached cells and debris were washed
with serum-free RPMI medium. The cells were then supple-
mented with or without TGF-β (5 ng/ml) containing RPMI
medium. Five random images per well were photographed
at 0h, 6h, 24h and 48h. The distance of the scratch was
measured in ImageJ software at every time point. The
wound distance at 0h was assigned as 100% and used
to calculate percent wound closure at other time
points. The P-value for statistical significance was
calculated by unpaired T-test.
Cell proliferation assay
H1299 cells stably expressing Runx2 or empty vector
treated control were counted in a hemacytometer and
1000 cells per well were seeded in a 96-well plate. To de-
termine the changes in proliferation, the cells were indir-
ectly assayed for cell number via a tetrazolium
compound-based colorimetric assay (CellTiter 96 kit
from Promega Inc. Madison, WI) according to manufac-
turer’s instructions. At indicated time points over a
period of four days, the cell titer reagent (20μl/well) was
added to the plate and incubated at 37°C for 1 hour. The
quantity of color developed (formazan product from the
tetrazolium compound) was measured by reading ab-
sorbance at 490 nm in a spectrophotometer (Fluostar
Optima BMG Labtech Inc. Cary, NC).
Immunoprecipitation:
Lung cancer H1299-WT-Runx2 or -shRunx2 cells were
washed with ice-cold PBS and harvested in lysis buffer
[50 mM NaCl, 50 mM Tris (pH 8.0), 1% NP- 40, 25
mM MG132, and 1× protease inhibitor mixture (Roche,
Indianapolis, IN)]. Lysates were incubated overnight at
4°C with 3 μg of rabbit antibodies against Runx2 antibody
(M-70, Santa Cruz Biotechnology Inc.), and Suv39h1
(Santa Cruz Biotechnologies). Lysates were then incubated
with protein A/G beads for 2 h, followed by four washes
with wash buffer [50 mM NaCl, 20 mM Tris (pH 8.3),
0.5% Na-deoxycholate, 0.5% Nonidet P-40, 2 mM EDTA,
25 mM MG132, and 1× protease inhibitor mixture]. The
total cell lysates and immunoprecipitated protein com-
plexes were resolved by 8% SDS/PAGE and transferred to
polyvinylidene difluoride membranes (Immobilon-P,
Millipore, Billerica, MA). Blots were incubated with
Runx2 (M-70) or Suv39h1 (C-14) antibodies. Membranes
were then incubated with HRP-conjugated secondary
antibodies against rabbit or mouse (1:2,000). Proteins
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tion kit (Perkin–Elmer Life Sciences,Waltham, MA).
Immunofluorescence
WI-38 and H1299 cells grown on gelatin coated cover
slips were processed for immunofluorescence microscopy
as previously described [31] using rabbit polyclonal Runx2
antibody (Santa Cruz Biotechnology, Inc.), followed
by incubation with Alexa 488 conjugated secondary
antibody (Molecular Probes, Eugene, OR). All images
were taken using a Zeiss Axioplan digital microscope
and analyzed using Metamorph software (Universal
Imaging, Downingtown, PA).
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